Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

HUMAN VACCINES - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Prophylatic Vaccines in US$ Million by the following product segments: Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin America. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report also analyzes the world market for Therapeutic Vaccines for the period 2010 to 2015. The report profiles 162 companies including many key and niche players such as ALK – Abelló A/S, Bavarian Nordic A/S, Crucell N.V., CSL Ltd., GlaxoSmithKline PLC, GlaxoSmithKline Biologicals S.A, Medimmune, Inc, Merck & Company, Inc., Novartis Vaccines & Diagnostics, Inc., Sanofi-Aventis S A, Sanofi-Pasteur SA, Sanofi Pasteur, Inc., Shanta Biotechnics Ltd., Vaxin, Inc., and Wyeth. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1176
Price : $4500
Companies : 162
Pages : 804
Date : January 2011
Market Data Tables : 117

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  HUMAN VACCINES (Complete Report) Pages : 804   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS......14 $295  
   Study Reliability and Reporting Limitations......1  
   Disclaimers......2  
   Data Interpretation & Reporting Level......3
Quantitative Techniques & Analytics......3
Product Definitions and Scope of Study......3
  
   Prophylactic Vaccines......4
Therapeutic Vaccines......4
  
  2. MARKET OVERVIEW & OUTLOOK.......57 $950  
   Human Vaccines Market Remains Resilient to Recession.......5
Global Human Vaccines Market: A Snapshot.......5
1$100
   Market Dynamics.......6
Vaccine Pricing: The Developed – Developing Divide.......6
1$100
   Global Market Analysis.......7
Growth Drivers in a Capsule.......7
Developed World: The Key Markets.......7
1$100
   Looking Ahead.......8
Emerging Markets: The Future Growth Area.......8
1$100
   Competitive Scenario.......9
World’s Leading Producers.......9
1$100
   Table 1: Leading Players in the Worldwide Vaccines Market (2008): Market Share Breakdown by Value Sales for GlaxoSmithKline, Sanofi-Aventis, Merck & Co., Novartis, Wyeth, and Others (includes corresponding Graph/Chart).......10
ALK- The Global Leader in Allergy Vaccines.......10
1$350
   Table 2: Leading Players in the Worldwide Allergy Vaccines Market (2005 & 2006 - A Historic Perspective): Market Share Breakdown of Value Sales (*) for ALK-Abelló, Stallergenes, Allergopharma, and Others (includes corresponding Graph/Chart).......11
1$350
  3. PRODUCT OVERVIEW.......1250 $4200  
   Introduction to the Concept of Immunity.......12
Role of Vaccines in Strengthening the Immune System.......12
1$100
   Vaccines and Immunotherapy.......13
Historical Overview of Vaccines.......13
How it Began.......13
2$200
   So Far So Good.......15
Successful Vaccine Introductions in the Past.......15
Contribution of Animal Research to Vaccine Production.......15
1$100
   Types of Vaccines.......161$100
   Live, Attenuated Vaccines.......171$100
   Combination Vaccines.......18
Killed or Inactivated Vaccines.......18
1$100
   DNA & Recombinant DNA Vaccines.......19
Toxoids.......19
Cellular Fractions.......19
Conjugate Vaccines.......19
1$100
   Subunit Vaccines.......20
Passive Immunization.......20
Prophylactic Vaccines.......20
Prevention Better than Cure.......20
1$100
   Prophylactic Pediatric Vaccines.......21
Vaccination Over the Years.......21
A Mature Market.......21
1$100
   Challenges for Pediatric Vaccines Market.......22
BCG Vaccine.......22
1$100
   Growth Boosting Factors for TB Vaccines.......23
Demand Restraining Factors for TB Vaccines.......23
Major Issues to be addressed in the TB Vaccine Market.......23
1$100
   Table 3: Global Historic Review for TB Vaccines Market: Annual Sales for Years 2000 through 2005 (In US$ Million) (includes corresponding Graph/Chart).......24
Hemophilus Influenza Type B Vaccine.......24
Hib and Combination Vaccines by Producer.......24
1$350
   Table 4: Historic Review for Pediatric Haemophilis Influenza B Vaccine Market in the US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart).......25

Table 5: Historic Review for Pediatric Haemophilis Influenza B Vaccine Market in the US: Annual Sales for 2000-2005 (In Million Doses) (includes corresponding Graph/Chart).......25
Diphtheria/Tetanus/Pertussis Vaccines.......25
1$350
   DTP, DTaP, and Combination Vaccines Offered by Major Producers in US.......26
Table 6: Leading Players in the US DTP and DTaP Vaccines Market (2003-2005 – A Historic Review): Market Share Breakdown of Value Sales (*) for Sanofi Pasteur, Wyeth*, GlaxoSmithkline, and Others (includes corresponding Graph/Chart).......26
1$350
   Table 7: Historic Review of DTP and DTaP Vaccines Market in the US: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart).......27

Table 8: Historic Review of DTP Vaccine Market in Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart).......27
Hepatitis A Vaccine.......27
1$350
   Hepatitis B Vaccine.......28
Hepatitis B Epidemiology.......28
Table 9: World Market for Hepatitis B Vaccines: Annual Sales for Years 2008 through 2015 (In US $ Million) (includes corresponding Graph/Chart).......28
1$350
   Table 10: Historic Review for Hepatitis B Vaccines Market in US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart).......29
Measles/Mumps/Rubella Vaccines.......29
1$350
   Table 11: Historic Review for Measles-Mumps-Rubella (MMR) Vaccine Market in US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart).......30

Table 12: Historic Review for Measles-Mumps-Rubella (MMR) Vaccine Market in the US: Annual Sales for 2000-2005 (In Millions of Doses) (includes corresponding Graph/Chart).......30
1$350
   Rotavirus Vaccines.......31
Polio Vaccines.......31
Table 13: Historic Review for Polio Vaccines Market in Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart).......31
1$350
   Table 14: Historic Review for Polio Vaccines Market in the US: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart).......32

Table 15: Historic Review for Polio Vaccine Market for Both Vaccine Types in the US: Annual Sales for 2000-2005 (In Million Doses) (includes correspondingGraph/Chart).......32

Table 16: Historic Review for Polio Vaccine Market for Both Vaccine Types (OPV and IPV) in the US in Percent of Doses from 2000-2005.......32
1$350
   Varicella Vaccine.......33
Table 17: Historic Review for Varicella Vaccine Market in the US and Europe: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart).......33
1$350
   Table 18: Historic Review for Varicella Vaccines Market in the US: Annual Sales for 2000-2005 (In Million Doses) (includes corresponding Graph/Chart).......34
Need for Combination Vaccines.......34
1$350
   Prophylactic Adult Vaccines.......35
Favorable Market Growth.......35
Hepatitis A Vaccine.......35
1$100
   Hepatitis B Vaccines.......361$100
   Key Issues Affecting the Adult Hepatitis Vaccines Market.......371$100
   Cholera Vaccine.......38
Hepatitis A/Hepatitis B Vaccine.......38
Japanese Encephalitis Vaccines.......38
Influenza Vaccines.......38
1$100
   Table 19: Global Flu Vaccines Market by Region (2005): Percentage Share Breakdown of Value Sales for the US, EU, and Rest of the World (includes corresponding Graph/Chart).......39

Table 20: Global Flu Vaccines Market by Leading Players (2005): Market Share Breakdown by Volume Sales for Sanofi Pasteur, Chiron, GSK and Others (includes corresponding Graph/Chart).......39
1$350
   Table 21: Rate of Influenza Vaccine Consumption Among Target Groups (includes corresponding Graph/Chart).......40

Table 22: Global Historic Review for Adult Influenza Vaccines: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart).......40
1$350
   Growth Boosting Factors for Influenza Vaccines Market.......41
Key Issues Affecting Influenza Vaccines Market.......41
Age-Driven Strategies Drive Target Market for Influenza Vaccines.......41
Healthcare Professionals Increase Target Market for Influenza Vaccines.......41
Lyme Disease Vaccine.......41
1$100
   Pneumococcal Disease Vaccines.......42
Meningococcal Vaccines.......42
1$100
   Rabies Vaccines.......43 1$100
   Table 23: Global Historic Review for Rabies Vaccines: Annual Sales for 2000-2005 (In US$ Million) (includes corresponding Graph/Chart).......44
Typhoid Vaccine.......44
Yellow Fever Vaccine.......44
Need for Additional Vaccines.......44
2$700
   Therapeutic Vaccines.......461$100
   DNA Holds the Key.......47
Huge Potential for Protein Based Vaccines.......47
Therapeutic Hepatitis Vaccines.......47
Therapeutic Addiction Vaccines.......47
Cancer Vaccines.......47
1$100
   Human Papillomavirus (HPV) Vaccine.......48
Breakthroughs in Cancer Vaccine Market.......48
1$100
   Factors Affecting the Market for Cancer Vaccines.......49
Vaccine for AIDS.......49
What is AIDS?.......49
Global Statistics.......49
1$100
   Table 24: Worldwide HIV/AIDS Estimates - 2007 (includes corresponding Graph/Chart).......50

Table 25: Worldwide HIV & AIDS Incidences (2007): A Regional Breakdown for Living and Newly Infected Cases (includes corresponding Graph/Chart).......50
1$350
   Table 26: Worldwide HIV & AIDS Prevalence Rate in Adults Aged between 15 and 49 Years for the Year 2007 (includes corresponding Graph/Chart).......51
Asia-Pacific.......51
1$350
   Central Asia & Eastern Europe.......52
Commonwealth of Independent States (CIS).......52
Latin America (Including the Caribbean Islands).......52
Sub Saharan Africa.......52
1$100
   North Africa & the Middle East.......53
Developed Regions and High-Income Countries.......53
United States.......53
Table 27: New HIV Infection Cases among Men in the US (2006): Percentage Breakdown by Mode of Infection (includes corresponding Graph/Chart).......53
1$350
   Table 28: New HIV Infection Cases in the US (2006): Percentage Breakdown by Racial/Ethnic Groups (includes corresponding Graph/Chart).......54

Table 29: New HIV Infection Cases among Women in the US (2006): Percentage Breakdown by Mode of Infection (includes corresponding Graph/Chart).......54
Development of Treatment Options.......54
Categories of Vaccines for AIDS.......54
1$350
   HIV Vaccines Under Development.......55
HIV Vaccines (Prophylactic/Therapeutic) Under Development: As of 2010.......55
Malaria Vaccine.......55
1$100
   Therapeutic Vaccines Against Infectious Diseases: The Challenges.......56
Melanoma: Prospects for Treatment.......56
Melanoma Vaccines under Development: As of 2010.......56
Autoimmune Diseases.......56
How Do Autoimmune Diseases Occur.......56
1$100
   Types of Autoimmune Diseases.......57
Need for Developing Autoimmune Therapeutic Vaccines.......57
Travel Vaccines: Opportunities.......57
SARS – A Review.......57
1$100
   Vaccinations Recommended for Travel to High-Risk Areas.......581$100
   Mechanisms for Vaccine Delivery.......59
Edible Vaccines.......59
2$200
   Oral Vaccines.......61
Tablet Based Vaccines.......61
Mucosal Delivery.......61
Transdermal Patch Delivery.......61
1$100
  4. MARKET TRENDS & ISSUES.......6213 $950  
   Newer Vaccines in Pipeline to Cheer Up Pharma Companies.......62
Select Vaccines Currently in Phase III Clinical Trials.......62
Threat of Pandemic Rejuvenates Vaccine Market.......62
1$100
   Influenza Vaccines On a Growing Spree.......63
H1N1 Vaccines Hit the Market in August 2009.......63
1$100
   H1N1 Influenza Vaccines and Manufacturers.......641$100
   Influenza Market Faces Several Challenges.......65
Economic Factors Hamper Optimal Vaccine Development and Delivery.......65
Increasing Need for Vaccine Promotion in the Developing Regions.......65
Changing Vaccine Needs.......65
1$100
   DNA Vaccines: Engineering Growth.......661$100
   AIDS Vaccine: Long Road Ahead.......671$100
   HIV Vaccines Research Clipped by Lack of Funds.......68
Funding Drops In HIV Vaccine Research Amid Recession.......68
Noninjectable Vaccines: Gain Without Pain.......68
Need for a Human Vaccine for Leishmaniasis.......68
1$100
   Conjugate Vaccines: A Technological Innovation.......69
Need For a New TB Vaccine.......69
Table 30: Worldwide Prevalence of TB Cases (in 000s) by Region for the Year (2007) (includes corresponding Graph/Chart).......69
1$350
   Companies Involved in TB Vaccine Research: As of 2010.......70
Religious Concerns Over Immunizing Young Girls Against Human Papillomavirus.......70
Changing Travel Patterns Increase Demand for Hepatitis B Vaccine.......70
1$100
   DTaP Vaccines Approved for Booster Vaccination.......71
Advances in Biotechnology Spearheading Vaccines’ Growth.......71
BioWarfare: Threat Perception and Preparedness.......71
1$100
   Overview of Potential Bio-Terrorist Agents.......72
Smallpox (Variola Major).......72
Anthrax (Bacillus Anthracis).......72
Plague (Yersinia Pestis).......72
1$100
   Botulism (Clostridium Botulinum).......73
Tularemia (Francisella Tularensis).......73
Market Concerns.......73
Safety Factor.......73
1$100
   Development Delays.......74
Storage Problems.......74
Perfluorocarbons as Alternative to Overcome Storage Problems.......74
Costs.......74
Standards for Vaccine Safety and Quality.......74
1$100
  5. DISTRIBUTION CHANNELS.......75   
   Distribution Channels.......75
1$100
  6. TECHNOLOGICAL DEVELOPMENTS.......766 $495  
   Applying Gene Therapy to Develop Therapeutic Solutions.......76
Research and Trials of AIDS Vaccines.......76
Ongoing Clinical Testing for AIDS Vaccines: Status As of 2010.......76
1$100
   International AIDS Vaccine Initiative (IAVI).......77
Cancer.......77
Cancer Type and Area Effected.......77
Immunotherapies for Cancer.......77
1$100
   Cancer Treatment Drugs.......78
Issues Effecting the Development of Commercially Viable Cancer Vaccines.......78
1$100
   Frequency of Vaccination.......79
Growth Boosters in the Cancer Vaccines Market.......79
1$100
   Available Cancer Treatment Vaccines.......80
Select Cancer Vaccines (Therapeutic and Prophylactic) in Clinical Trials: As of
  2010.......80
1$100
   Other Cancer Treatment Vaccines.......81
Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines.......81
1$100
  7. CLINICAL TRIALS IN THE VACCINES MARKET.......8214 $950  
   Vaccinogen Selects Clinipace for Phase 3b Clinical Trial with OncoVAX.......82
BioSante to Restart Prostate Cancer Vaccine Clinical Testing.......82
University of Oxford to Commence Phase 2b Proof-of- Concept Clinical Trials with TB
  Vaccine in Infants.......82
1$100
   Emergent Begins Phase I/II Clinical Studies of AIG for Anthrax Treatment.......83
Favrille Announces Phase III Registration Trial Results of Specifid in Patients with
  Follicular B-Cell Non-Hodgkin's Lymphoma.......83
Novartis Announces Phase III Results of Menveo® Vaccine.......83
1$100
   Emergent Commences Phase II Clinical Study of Typhoid Vaccine.......84
AVANT’s Single-Dose Oral Ty800 Vaccine Meets Key Endpoints.......84
Emergent BioSolutions’ Typhoid Vaccine Completes Final Phase II Clinical Trial.......84
1$100
   Antigenics Announces Positive Data on Phase-I Study of ACAM-FLU-ATM Vaccine.......85
Bavarian Nordic’s IMVAMUNE® Post-Exposure Vaccination Demonstrates Protection Against
  Fatal Poxvirus Infection.......85
1$100
   BSU Scientists to Commence Human West Nile Vaccine Development Project.......86
Intercell Concludes First Phase Clinical Studies of IC31® Adjuvanted Influenza
  Vaccine.......86
Protherics Commences Phase 2 Angiotensin Vaccine Study.......86
1$100
   Novartis Receives European Approval for Optaflu® Flu Vaccine.......87
CSL Biotherapies Files BLA for Influenza Vaccine.......87
Orchestra Therapeutics Abandons Development of HIV Vaccine.......87
AlphaVax Concludes Phase I Clinical Trial of Flu Vaccine.......87
1$100
   AVANT Presents Preclinical Data on Enteric Vaccine.......88
Baxter Declares Results of Seasonal Flu Vaccine Candidate Trial.......88
1$100
   IDM Pharma Announces Interim Data of Phase II Clinical Trials of Lung Cancer
  Vaccine.......89
1$100
   Novavax Announces Developments in Discovery Program.......90
Acambis Pioneers Testing of West Nile Virus Vaccine in Grown Ups.......90
Acambis Initiates Test of single-dose JE vaccine in India.......90
AVAX Technologies Initiates Phase 3 Clinical Trial For M-Vax.......90
1$100
   LigoCyte Pharmaceuticals Begins Clinical Testing of Norovirus Vaccine.......91
Alphavax Initiates Clinical Testing for Flu and CMV Vaccines.......91
Sanofi Pasteur Begins Phase 2 Testing of New Influenza Vaccine.......91
1$100
   Antigenics Reveals the Preliminary Data of Clinical Trial of Oncophage®.......92
Baxter Reveals Phase I/II Clinical Trial Results of H5N1 Pandemic Vaccine.......92
Crucell and AERAS Initiates Tuberculosis Vaccine Clinical Trial.......92
DOR BioPharma Announces Phase I Results of RiVax™.......92
1$100
   GlaxoSmithKline Starts Clinical Trials to Test H5N1 Pandemic Flu Vaccines.......93
MedImmune Initiates Phase I Clinical Trial of Avian H5N1 Vaccine.......93
MedImmune Reveals Results of Phase 3 Study for CAIV-T.......93
MedImmune Initiates Second Phase 1 Study with MEDI-534.......93
1$100
   Sanofi Pasteur Initiates First Clinical Trial of Cell Based H7N1 Vaccine.......94
Therion Biologics Completes Enrollment for Phase III trials of PANVAC-VF.......94
ViRexx Finishes the Treatment in Phase I Study of HepaVaxx B Vaccine.......94
Antigenics Begins Phase I Clinical Trial of AG-707.......94
Positive Results in Novavax’s Pandemic Influenza Vaccine Pre-clinical Trials.......94
1$100
   Trials Reveal H5N1 Pre-Pandemic Vaccine of Sanofi Pasteur Effective.......95
PowderMed Reveals Reveals for Phase 1 Trials for Influenza Vaccine.......95
Phase II clinical trials of China's hepatitis B vaccine.......95
1$100
  8. RESEARCH BREAKTHROUGHS IN RECENT PAST – A PERSPECTIVE BUILDER.......96   
   Findings Prove New Nose-Spray Vaccines Effective.......96
Large Doses of H5N1 Influenza Vaccine Appears Effective.......96
New Vaccine Technology to Prevent TB.......96
HPV Vaccine to Help Prevent Cervical Cancer.......96
Scientists Develop H7N1 Avian Influenza Vaccine.......96
1$100
   Human H5N1 Vaccine Developed by Central Hygiene and Epidemiology Institute.......97
1$100
  9. PRODUCT DEVELOPMENT/LAUNCHES.......98   
   Vivalis and SAFC Launch Ex-Cell EBx Media.......98
MSD Pharmaceuticals India Launches GARDASIL Vaccine.......98
Sanofi-Aventis Introduces ActHIB Vaccine in Japan.......98
Sinovac Biotech Introduces Anflu®.......98
1$100
   Nventa Biopharmaceuticals Develops Poly IC-Poly Arginine.......99
Replikins Develops New Synthesized Vaccine.......99
GlaxoSmithKline Biologicals Launches Cervarix.......99
CSL Develops New Vaccine for Prevention of Bird Flu.......99
1$100
  10. PRODUCT DEVELOPMENT/LAUNCHES IN RECENT PAST – A PERSPECTIVE BUILDER.......1004 $295  
   GlaxoSmithKline to Introduce Five Key Medicines for Oncology.......100
FFF Enterprises Unveils My Flu Vaccine Network.......100
Nabi Biopharmaceuticals to Develop NicVax Vaccine for Reducing Nicotine
  Effects.......100
GenPhar Develops Highly Effective Tetravalent Dengue Vaccine.......100
1$100
   Iomai Commences the Development of Prophylactic Traveler™s Diarrhea Vaccine.......101
Biological Immunological to Produce and Sell r-Hepatitis B Vaccine.......101
Thailand Researchers Commence the Development of Human Bird Flu Vaccine.......101
USV to Commercialize Typhoid Vaccine.......101
ALK-Abelló Introduces GRAZAX® Anti-Allergy Vaccine.......101
1$100
   Novartis Unveils Influenza Virus Vaccine Fluvirin®.......102
Wyeth Introduces Latest 7-in-1 Pneumococcal Conjugate Vaccine.......102
Intervet Releases Arnhem, a Prototype of Avian Influenza Vaccine.......102
Shantha Launches ‘Jencevac’ Brain Fever Vaccine.......102
1$100
   Wockhardt and Zhejiang Introduces New Hepatitis-A Vaccine.......103
GSK Introduces Rotarix(R) Vaccines for Infants.......103
Sinovac Biotech Introduces Bilive™.......103
1$100
  11. RECENT INDUSTRY ACTIVITY.......10421 $1450  
   Dendreon Receives FDA Approval for PROVENGE® to Treat Men with Advanced Prostate
  Cancer.......104
SVA and Parenteral Biotech Enter into a Partnership to Distribute and Supply
  Vaccines.......104
Novartis Obtains FDA Approval for Menveo® Vaccine.......104
1$100
   Pfizer to Supply Vaccine for Pneumococcal Disease.......105
Torii Enters into Partnership with Riken.......105
Sanofi-Aventis Acquires Shantha Biotechnics.......105
Affitech AS Merges with Pharmexa A/S.......105
1$100
   Takeda Acquires IDM Pharma.......106
Pfizer Concludes Wyeth’s Acquisition.......106
Sanofi Pasteur and Syntiron Sign Agreement to Develop and Market Prophylactic
  Vaccine.......106
Cell Genesys Merges with BioSante Pharmaceuticals.......106
1$100
   Simcere Pharmaceutical Acquires Controlling Stake in ChinaVax.......107
Novartis to Acquire 85% Stake in Zhejiang Tianyuan.......107
FDA Approves Merck’s Gardasil for Males under 9 to 26 Years Age.......107
Merck Sign Agreement with CSL Biotherapies.......107
Sinovac Forms JV with Dalian to Develop and Market Human-Use Vaccines.......107
1$100
   CPL Enters Into JV with Novavax.......108
Nobilon Ties-up with WHO.......108
GeoVax Labs to Relocate Operations.......108
SingVax and Inviragen Merge.......108
1$100
   Sanofi-aventis and Mexican Authorities Enter into Agreement.......109
Kitasato Institute and Daiichi Sankyo Ink Agreement.......109
ACVD to Enter into Alliance with Emory Vaccine Center.......109
Emory University to Set Up Emory Institute for Drug Discovery.......109
ImmunoVaccine Technologies Enters into Partnership with FIT Biotech.......109
1$100
   VGX Pharmaceuticals Merges with Inovio Biomedical.......110
Sanofi Pasteur Obtains EC Approval for INTANZA®/IDflu®.......110
European Commission Grants Marketing Authorization to Ixiaro® Vaccine.......110
US FDA Approves Ixiaro® Vaccine.......110
Emergent BioSolutions Purchases Protein Sciences.......110
1$100
   Vaccine Technologies Signs Agreement with Celldex Therapeutics.......111
Oxford-Emergent Tuberculosis Consortium and ProBioGen Ink Agreement.......111
JN-International to Acquire Biocor’s Vaccine Research and Manufacturing Plant.......111
1$100
   Mymetics to Acquire Bestewil Holding BV.......112
Eureka Genomics and Nanobac Pharmaceuticals to Merge.......112
Immunovaccine Enters into Agreement with National Cancer Institute.......112
GSK Forms Joint Venture with Walvax.......112
AVANT Adopts New Identity as Celldex Therapeutics.......112
1$100
   Eli Lilly Takes Over ImClone Systems.......113
Sanofi Pasteur Acquires Acambis.......113
Novartis to Acquire Protez.......113
1$100
   Novartis Inks Agreement with AlphaVax.......114
Vacsera Signs Agreement with Omninvest.......114
GeoVax Sign LOI with Vivalis.......114
GlaxoSmithKline Receives EC Approval for Prepandrix Vaccine.......114
1$100
   ShigaMedix SAS and Avesthagen Sign Agreement.......115
Shenzhen Neptunus Inks Agreement with GlaxoSmithKline.......115
Sanofi Pasteur Establishes Vaccine Manufacturing Facility.......115
Emergent BioSolutions Forges Joint Venture with the University of Oxford.......115
1$100
   Crucell Bags Contract from NIAID and NIH.......116
PharmAthene Takes Over Business of Avecia.......116
Crucell and Wyeth Pharmaceuticals Sign Agreement.......116
Cytos Biotechnology and Pfizer Vaccines Sign Agreement.......116
Intercell Acquires Iomai.......116
1$100
   Emergent BioSolutions to Acquire Recombinant Flu Vaccine, FluBlok®.......117
Encorium Group Signs Contract with Protherics.......117
Beijing Keyuan Xinhai Pharmaceutical Signs Agreement with China Biopharma.......117
1$100
   Callisto Merges with Celldex.......118
Mymetics Corp. Buys Preventive Malaria Vaccine of Pevion Biotech AG.......118
Dynavax Inks Agreement with Novartis.......118
NasVax to Buy Protea Vaccine Technologies.......118
Paladin Labs Buys ViRexx Medical Corp........118
1$100
   Emergent BioSolutions Acquires Group of Anthrax Monoclonal Antibodies from
  AVANIR.......119
China Biopharma and BKXPC Enter into Agreement.......119
Encorium Signs Contract with Protherics for Phase 2 Trial of ATV for
  Hypertension.......119
1$100
   GenPhar to Establish Vaccine Production Plant in South Carolina.......120
Intercell Partners SSI and Sanofi Pasteur to Further Develop TB Vaccine.......120
Intercell and PATH Malaria Vaccine Initiative Form New Partnership for Malaria
  Vaccine.......120
1$100
   Intercell Receives Manufacturer's License for Production of JE Vaccine.......121
GSK Receives US FDA Approval for ROTARIX® Rotavirus Vaccine.......121
1$100
   Dynavax and Merck & Co Announce Clinical Hold of HEPLISAV Vaccine Trial.......122
Pharmexa and Ichor Enter into Co-Development Agreement for Multiple DNA
  Vaccines.......122
1$100
   Crucell Enters into Exclusive Development Agreement with Wyeth
  Pharmaceuticals.......123
Crucell and Sanofi Ink an Agreement for Advanced Anti-Rabies Biologicals.......123
FDA Confers Priority Designation for Supplemental Application for GARDASIL ®.......123
1$100
   Sanofi Submits a European Marketing Approval Application for First Influenza
  Vaccine.......124
1$100
  12. CORPORATE ACTIVITY IN THE RECENT PAST – A PERSPECTIVE BUILDER.......12533 $1950  
   Lonza Consolidates Micobial Biopharma Operations.......125
Novartis Acquires Rights Over a Novel Therapeutic Vaccine Candidate.......125
AstraZeneca Purchases MedImmune.......125
Nobilon Purchases EBx™ Cell Lines Rights from Vivalis.......125
1$100
   NasVax Inks Partnership Agreement with SciGen.......126
GSK Inks Co-Promotion Agreement with Sinovac Biotech for Anflu.......126
Pfizer Buys Coley Pharmaceutical Group.......126
FDA Selects sanofi’s H5N1 Vaccine.......126
Novartis Starts Construction of a Cell-Culture Based Vaccine Production
  Facility.......126
1$100
   IVT Signs an MoU to Take Over Immunotope.......127
Oxford BioMedica Takes Over Oxxon Therapeutics.......127
DND Issues RFP for acquisition of MVA-based smallpox vaccine.......127
1$100
   GlaxoSmithKline Acquires Reliant Pharmaceuticals.......128
GSK Acquires Praecis Pharmaceuticals.......128
Berna Biotech Divests Stake in Pevion Biotech.......128
GeoVax Signs a Private Placement Agreement with Pure Capital.......128
1$100
   Crucell Inks a Research License Agreement with ISU ABXIS of Korea.......129
China Biopharma Concludes Capital Funding to ZT Biotech.......129
Crucell and Acambis Ink a Licensing Agreement for PER. C6 ® Technology.......129
Novartis and Intercell Join Hands to Advance Vaccine Programs.......129
1$100
   Serum Institute and Akorn Ink MoU for Vaccine Commercialization in US Market.......130
Merck Plans to Establish a Human Vaccine Facility in Ireland.......130
Schering-Plough Acquires Organon Bio Sciences.......130
1$100
   Intas Biopharmaceuticals Enters into Collaboration Agreement with Virionics.......131
Oxxon Therapeutics Starts U.S. Operation.......131
GenPhar and ImmuneRegen Enter into Research Partnership.......131
Intercell Submits BLA for JE Vaccine to US FDA.......131
1$100
   AVANT and Select Vaccines Enter into R&D Partnership.......132
AVAX Enters into Agreement with Cancer Treatment Centers of America.......132
1$100
   CSC’s DVC and Baxter Receive Contract Modification from U.S. HHS.......133
DOR BioPharma Enters into CRADA with Walter Reed Army Institute.......133
1$100
   Dynavax and Merck to Enter into Partnership to Develop Hepatitis B Vaccine.......134
Emergent BioSolutions Commences Delivery of BioThrax® to US Health Department.......134
1$100
   Maxygen and Sanofi Pasteur sign License Agreement.......135
Beijing Public Health Bureau Enters into Purchase Agreement with Sinovac.......135
Novartis Wins US Government Contract for Developing Antigen Technology.......135
1$100
   MedImmune Announces Licensing of Reverse Genetics Technology to
  GlaxoSmithKline.......136
MedImmune Wins US Government Contract.......136
1$100
   MedImmune and Human Genome Sciences Sign Lease Agreement.......137
Acambis Announces Signing of Collaboration Agreement with Sanofi Pasteur.......137
Acambis Announces JE Partnership Agreement with Sanofi Pasteur.......137
1$100
   Crucell Procures Major Patent for Influenza Vaccine Production.......138
CSL Receives FDA Approval for Influenza Virus Vaccine.......138
GlaxoSmithKline Inks Contract with UK Government.......138
1$100
   Merck & Co., Inc. and Dynavax to Jointly Develop Hepatitis B Vaccine.......139
Sanofi Pasteur Wins Contract to Design, Retrofit and Maintain Influenza Vaccine
  Unit.......139
1$100
   Sanofi Pasteur Completes Construction of Influenza Vaccine Production Unit.......140
Amgen Acquires Abgenix.......140
Pfizer Acquires PowderMed.......140
CancerVax and Micromet Merge to Establish Micromet, Inc........140
Novartis Acquires Chiron.......140
1$100
   Dynavax Takes Over Rhein Biotech.......141
AnGes and Vical Ink Collaborative Agreement.......141
GeoVax Merges with Dauphin.......141
Hawaii Biotech and Avantogen Merge to Form New Entity.......141
CytoDyn Acquires Advanced Influenza Technologies.......141
Emergent BioSolutions Acquires VIVACS.......141
1$100
   Acambis Divests Berna Business to Crucell.......142
Novavax Inks an Agreement with Bharat Biotech to Develop Avian Flu Vaccine.......142
Aeras Receives License for Developing and Distributing Tuberculosis Vaccine.......142
Acambis to Supply Smallpox Vaccine to CDCP.......142
AlphaVax and Wyeth Enhance Existing Licensing Agreement.......142
1$100
   Baxter Enters into a Contract to Supply Pandemic Influenza Vaccine.......143
Sanofi Pasteur Signs Stockpile Contract with the US Government.......143
Crucell Licenses PER.C6® Technology to ADImmune Corporation.......143
Baxter Wins Stockpile Production Contract for H5N1 from the NHS.......143
Crucell Earns NIH Contract to Develop HIV Vaccine.......143
1$100
   Novartis Secures Stockpile Supply Contract from the US Government.......144
Novartis Signs Distribution Agreement with Intercell.......144
GSK Receives Stockpile Supply Contract for Fly Pandemic from the HHS.......144
GSK Signs H5N1 Antigen Influenza Vaccine Contract with Switzerland.......144
1$100
   DOR BioPharma Forms Alliance to Develop Ricin Vaccine.......145
Nobilon and NVI to Jointly Develop RSV Vaccine.......145
SciGen and OctoPlus Join Forces to Develop Hepatitis B Vaccine Delivery.......145
1$100
   AlphaVax Receives Patent for Alphavaccines Manufacturing Process.......146
IVI Receives Funds for Cholera Vaccine Development Program.......146
Novavax Forms Strategic Alliance with US-based, PacificGMP.......146
Sanofi Pasteur Enters into Partnership with PDVI.......146
1$100
   MedImmune Inks a Cooperative R&D Agreement with NIAID.......147
MedImmune Bags a Five-Year HHS Contract.......147
Novavax Enters into a Cooperative Research Agreement with CDC.......147
GlaxoSmithKline Establishes New Vaccine Manufacturing Facility.......147
1$100
   GenPhar Extends R&D Contract with NMRC.......148
Medlmmune Files for INDA with FDA for a New Influenza Vaccine.......148
Rotarix™ Vaccines Receives European Approval.......148
Merck’s GARDASIL® Receives FDA Approval.......148
1$100
   CDC Adds Merck’s GARDASIL® Under its VFC Category in the US.......149
Medlmmune Submits sBLA to the FDA Refrigerator-Stable Influenza Vaccine.......149
Medlmmune Submits sBLA to the FDA for Expanded Label for CAIV-T.......149
Medlmmune Receives FDA Approval for the Use of Reverse Genetics Technology.......149
Vivalis Starts a New Plant in France to Produce Viral Vaccines.......149
1$100
   Fiocruz Provides Yellow-Fever Vaccine to Peruvian Government.......150
Merck Receives FDA Approval for Zostavax Vaccine.......150
The US Health and Human Services Department Awards Grant to Pharma Companies.......150
GlaxoSmithKline Expands License and Supply Agreement with Antigenics.......150
GlaxoSmithKline Applies for Approval for Cervical Cancer Vaccine.......150
1$100
   Omnia Biologics Signs Deal with Aeras Global TB Vaccine Foundation.......151
Aeras Alliances with Dutch Scientific Organizations to Develop Latest TB
  Vaccines.......151
Embrex, Shenzhen, and P.R. China Team Up for Manufacturing Influenza Vaccine.......151
Health Canada Grants Approval to Merck’s RotaTeq.......151
HepaLife Technologies Receives License for Technology from MSU.......151
1$100
   Hindustan Latex Ties-up with Bharat Biotech for Marketing Vaccines.......152
Emergent BioSolutions and Sanofi Pasteur Sign Agreement.......152
USV and BCIL Enter into Agreement.......152
GenVec Receives Fifth-Year Extension of Contract from NIAID.......152
Inovio Joins Hands with Tripep to Develop Hepatitis C Vaccine.......152
1$100
   Novavax and Bharat Biotech Form Alliance to Develop Pandemic Flu Vaccine.......153
Panacea Biotech Joins Hands with NVI to Create Polio Vaccine.......153
Immune Response Ties Up with Accelsiors for Trial of NeuroVax Vaccine.......153
Nordic Vaccine Joins Forces with Ace BioSciences to Develop Efficient
  Vaccines.......153
1$100
   Eisai Partners with DNAVEC to Develop New Vaccine.......154
ViRexx Partners with DRDC to Develop Biodefence Vaccines.......154
Biovirx Teams Up with IDT to Reintroduce Vaccine for Infants.......154
LG Life Sciences Enters into Agreement with Sinovac.......154
1$100
   MediGene Awards Licenses to Virionics for CVLP Vaccine Program.......155
FluLaval Influenza Vaccine Receives FDA Approval.......155
Merck Applies for Approval to Market Gardasil in China.......155
Bio-Bridge Establishes New Vaccine Facility in China.......155
SIIL Established the First-ever Biotech SEZ in India.......155
1$100
   Aeras Foundation Establishes New Laboratory for TB Vaccine.......156
China Biopharma Distributes Flu Vaccine in China.......156
ViroPro Founds New Subsidiary for Developing Medicinal Vaccines.......156
Glaxosmithkline Acquires Corixa Corporation.......156
1$100
   GSK Acquires ID Biomedical.......157
Pharmexa Acquires GemVax.......157
1$100
  13. FOCUS ON SELECT GLOBAL PLAYERS.......15812 $950  
   ALK – Abelló A/S (Denmark).......158
Bavarian Nordic A/S (Denmark).......158
1$100
   Crucell N.V. (The Netherlands).......159
CSL Ltd. (Australia).......159
1$100
   GlaxoSmithKline PLC (UK).......1602$200
   GlaxoSmithKline Biologicals S.A (Belgium).......162
Medimmune, Inc. (USA).......162
Merck & Company, Inc. (USA).......162
1$100
   Novartis Vaccines & Diagnostics, Inc. (USA).......1631$100
   Sanofi-Aventis SA (France).......1642$200
   Sanofi Pasteur, SA (France).......1661$100
   Sanofi Pasteur Inc. (USA).......1671$100
   Shantha Biotechnics Ltd. (India).......1681$100
   Vaxin, Inc. (USA).......169
Wyeth (USA).......169
1$100
  14. GLOBAL MARKET PERSPECTIVE.......170   
   Table 31: World Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1701$350
   Table 32: World Historic Review for Human Vaccines (Prophylactic) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......1711$350
   Table 33: World 11-Year Perspective for Human Vaccines (Prophylactic) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......1721$350
   Table 34: World Recent Past, Current & Future Analysis for Prophylactic Vaccines by Product Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1731$350
   Table 35: World Historic Review for Prophylactic Vaccines by Product Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......174

Table 36: World 11-Year Perspective for Prophylactic Vaccines by Product Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2005, 2010 & 2015.......174
1$350
   Table 37: World Recent Past, Current & Future Analysis for Pediatric Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1751$350
   Table 38: World Historic Review for Pediatric Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......1761$350
   Table 39: World 11-Year Perspective for Pediatric Prophylactic Vaccines by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......1771$350
   Table 40: World Recent Past, Current & Future Analysis for Adult Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......1781$350
   Table 41: World Historic Review for Adult Prophylactic Vaccines by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......1791$350
   Table 42: World 11-Year Perspective for Adult Prophylactic Vaccines by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).......1801$350
   Table 43: World Recent Past, Current & Future Analysis for Human Vaccines (Therapeutic) – Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2015 (includes corresponding Graph/Chart).......181
1$350
  15. THE UNITED STATES.......18224 $3950  
   A. Market Analysis.......182
Outlook.......182
Current & Future Analysis.......182
Growth Drivers.......182
1$100
   Market Constraints.......183
Supply Shortages Mar Vaccines Market in Early Part of the Decade.......183
Pediatric Vaccines Market.......183
Market Focus Shifting From Pediatric Vaccines.......183
Growth Drivers for US Pediatric Vaccines Market.......183
1$100
   Demand Restraining factors for US Pediatric Vaccines Market.......184
Table 44: US Historic Review for Pediatric Vaccines: Annual Sales (In Millions of Doses) for Years 2000 through 2005 (includes corresponding Graph/Chart).......184
1$350
   Table 45: US Pediatric Vaccines by Type in terms of Percent of Doses: 2000-2005 (includes corresponding Graph/Chart).......185
‘Bright’ Outlook for Therapeutic Vaccines.......185
1$350
   Select Cancer Vaccines in Pipeline in the US: As of 2010.......186
Market Share of Key Players in North America.......186
Table 46: Leading Players in the North American Human Vaccines Market (2005 – A Recent Past Review ): Market Share Breakdown of Value Sales for Merck, Sanofi-Aventis, Wyeth, GlaxoSmithKline, and Others (includes corresponding Graph/Chart).......186
The US Influenza Vaccine Market.......186
1$350
   Table 47: The US Influenza Vaccine Market: Production and Distribution of Influenza Vaccine (In Millions) for the Period 2000-2001 to 2007-2008 (includes corresponding Graph/Chart).......187
US DHHS Allocates US$1 Billion for Developing H1N1 Vaccine in 2009.......187
1$350
   2007-2008 Influenza Vaccine Season.......188
Table 48: Influenza Vaccine Producers for the Influenza Season (2007-2008): Market Share Breakdown in Production Terms for Sanofi Pasteur, Novartis, GlaxoSmithKline, MedImmune, and CSL (includes corresponding Graph/Chart).......188
2005-2006 Influenza Vaccine Season.......188
1$350
   Table 49: Funds Forwarded by HHS for Influenza Vaccine Production (2005-2006) to Key Vaccine Manufacturers (In US Dollars) (includes corresponding Graph/Chart).......189
Influenza Vaccine Producers for the 2006-2007 Influenza Season.......189
Problems Effecting Timely Supply of Influenza Vaccine.......189
Table 50: Influenza Vaccines Market in the US (2005 – A Recent Past Perspective): Percentage Breakdown of Value Sales for Sanofi Aventis, Chiron*, GSK, and Medimmune (includes corresponding Graph/Chart).......189
1$350
   Key Statistics.......190
Table 51: Number of Children (In Millions) Under 5 Years of Age in the US:: 2000-2005 (includes corresponding Graph/Chart).......190
1$350
   Vaccines and Intended User Group.......191
Need for Immunization Schedule for Adults.......191
1$100
   Adult Population: To Drive Future Growth of Pertussis Vaccines Market.......192
Table 52: Pertussis Cases (In Millions) for Years 2000 through 2008 (includes corresponding Graph/Chart).......192
Federal Research & Grants.......192
National Cancer Institute.......192
National Institutes of Health (NIH).......192
1$350
   NIH Scientists Showcase Potential West Nile Virus Vaccine.......193
NIH Doles Out Grants to Biotech Companies.......193
Development Funds for HIV Vaccines- Recent Past Data.......193
Development Funds for Biodefense-Related Vaccines-Recent Past Data.......193
1$100
   The National Institute of Allergy and Infectious Diseases (NIAID).......194
Intramural Research.......194
Extramural Divisions.......194
Vaccine Pricing in the US.......194
1$100
   Table 53: Vaccine Prices (In US$ per Dose) in the US: 2002-2005 (includes corresponding Graph/Chart).......195
Regulatory Environment.......195
Review Process Make Vaccines Safer.......195
Imports-Exports Scenario: A Historic Perspective.......195
Exports of Human Vaccines for 2004.......195
Table 54: US Domestic Exports of Vaccines for Human Medicine for the Year 2004 (Value in ‘000 US Dollars) (includes corresponding Graph/Chart).......195
1$350
   Imports of Human Vaccines for 2004.......196
Table 55: US Imports of Vaccines for Human Medicine for the Year 2004 (Value in ‘000 US Dollars) (includes corresponding Graph/Chart).......196
Select Players.......196
Alphavax, Inc........196
Antigenics, Inc........196
1$350
   Avax Technologies, Inc........197
Baxter International, Inc........197
1$100
   Celldex Therapeutics, Inc........198
Dendreon Corporation.......198
1$100
   Dynavax Technologies Corp........199
Emergent BioSolutions Inc........199
1$100
   GenPhar, Inc........200
Ligocyte Pharmaceuticals, Inc.......200
1$100
   Maxygen, Inc........201
Micromet, Inc........201
1$100
   Novavax, Inc........202
Progenics Pharmaceuticals, Inc........202
1$100
   Soligenix, Inc........2031$100
   B. Market Analytics.......204
Table 56: US Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......204
1$350
   Table 57: US Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment –Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......205

Table 58: US 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......205
1$350
  16. CANADA.......2063 $595  
   A. Market Analysis.......206
2009 H1N1 Pandemic Boosts Vaccines Sales.......206
H1N1 Vaccines Approved For Use in Canada.......206
1$100
   B. Market Analytics.......207
Table 59: Canadian Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......207
1$350
   Table 60: Canadian Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......208

Table 61: Canadian 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......208
1$350
  17. JAPAN.......2092 $595  
   Market Analysis.......209
Table 62: Japanese Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......209
1$350
   Table 63: Japanese Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......210

Table 64: Japanese 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......210
1$350
  18. EUROPE.......2119 $2450  
   A. Market Analysis.......211
Overview.......211
Table 65: Leading Players in the West European Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, Novartis, and Others (includes corresponding Graph/Chart).......211
Vaccine Pricing in Europe.......211
Major Drawbacks.......211
1$350
   Current & Future Analysis.......212
Regulatory Mechanism for Vaccines in Europe.......212
Sanofi Pasteur MSD (Europe) – A Leading Player.......212
1$100
   Market Share Statistics by Vaccines Category.......213
Table 66: Leading Players in the European Pediatric Vaccines Market (2008): Market Share Breakdown of Value Sales for GlaxoSmithKline, Wyeth, Sanofi Pasteur MSD, and Others (includes corresponding Graph/Chart).......213

Table 67: Leading Players in the European HPV Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, and GlaxoSmithKline.......213

Table 68: Leading Players in the European for Flu, and Other Adult Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, Novartis, Solvay, and Others (includes corresponding Graph/Chart).......213
1$350
   Table 69: Leading Players in the European Booster Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, and Others (includes corresponding Graph/Chart).......214

Table 70: Leading Players in the European Travel Vaccines Market (2008): Market Share Breakdown of Value Sales for GlaxoSmithKline, Sanofi Pasteur MSD, and Others (includes corresponding Graph/Chart).......214
1$350
   B. Market Analytics.......215
Table 71: European Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Geographic Region – France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......215
1$350
   Table 72: European Historic Review for Human Vaccines (Prophylactic) by Geographic Region – France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......2161$350
   Table 73: European 11-Year Perspective for Human Vaccines (Prophylactic) by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart).......2171$350
   Table 74: European Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......2181$350
   Table 75: European Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......219

Table 76: European 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......219
1$350
  18a. FRANCE.......2203 $950  
   A. Market Analysis.......220
Table 77: Leading Players in the French Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, Wyeth, GlaxoSmithKline, and Others (includes corresponding Graph/Chart).......220
1$350
   B. Market Analytics.......221
Table 78: French Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......221
1$350
   Table 79: French Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......222

Table 80: French 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......222
1$350
  18b. GERMANY.......2233 $950  
   A. Market Analysis.......223
Table 81: Leading Players in the German Vaccines Market (2008): Market Share Breakdown of Value Sales for GlaxoSmithKline, Sanofi Pasteur MSD, Novartis, Wyeth, and Others (includes corresponding Graph/Chart).......223
1$350
   B. Market Analytics.......224
Table 82: German Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......224
1$350
   Table 83: German Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......225

Table 84: German 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......225
1$350
  18c. ITALY.......2263 $950  
   A. Market Analysis.......226
Table 85: Leading Players in the Vaccines Market in Italy (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, Novartis, and Others (includes corresponding Graph/Chart).......226
1$350
   B. Market Analytics.......227
Table 86: Italian Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......227
1$350
   Table 87: Italian Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......228

Table 88: Italian 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......228
1$350
  18d. THE UNITED KINGDOM.......2294 $950  
   A. Market Analysis.......229
Table 89: Leading Players in the Vaccines Market in the UK (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, and Others (includes corresponding Graph/Chart).......229
The UK Vaccine Industry Group (UVIG).......229
Select Players.......229
BioVex.......229
1$350
   Oxford Biomedica PLC.......2301$100
   B. Market Analytics.......231
Table 90: UK Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......231
1$350
   Table 91: UK Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figuresin US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......232

Table 92: UK 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......232
1$350
  18e. SPAIN.......2333 $950  
   A. Market Analysis.......233
Table 93: Leading Players in the Vaccines Market in Spain (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, and Others (includes corresponding Graph/Chart).......233
1$350
   B. Market Analytics.......234
Table 94: Spanish Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......234
1$350
   Table 95: Spanish Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......235

Table 96: Spanish 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......235
1$350
  18f. RUSSIA.......2363 $950  
   A. Market Analysis.......236
Table 97: Leading Players in the Russian Vaccines Market (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur, GlaxoSmithKline, Merck & Co., Novartis, and Others (includes corresponding Graph/Chart).......236
1$350
   B. Market Analytics.......237
Table 98: Russian Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......237
1$350
   Table 99: Russian Historic Review for Human Vaccines (Prophylactic) by Product Group/ Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......238

Table 100: Russian 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......238
1$350
  18g. REST OF EUROPE.......2394 $950  
   A. Market Analysis.......239
Table 101: Leading Players in the Vaccines Market in Rest of Europe (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur MSD, GlaxoSmithKline, Wyeth, and Others (includes corresponding Graph/Chart).......239
Select Player.......239
Intercell AG (Austria).......239
2$700
   B. Market Analytics.......241
Table 102: Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......241
1$350
   Table 103: Rest of Europe Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment – Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......242

Table 104: Rest of Europe 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/ Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart).......242
1$350
  19. ASIA-PACIFIC.......24311 $1950  
   A. Market Analysis.......243
Asian Vaccine Industry.......243
Challenges.......243
China.......243
1$100
   Table 105: Leading Players in the Vaccines Market in China (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur, GlaxoSmithKline, and Others (includes corresponding Graph/Chart).......244
Growth Drivers.......244
Table 106: Central Government Funding for National Immunization Program (2004-2008) (includes corresponding Graph/Chart).......244
1$350
   State Drug Administration: Regulatory Authority in China.......245
India.......245
1$100
   Table 107: Leading Players in the Vaccines Market in India (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur (plus Shanta), GlaxoSmithKline, Serum Institute of India, Novartis, Panacea, Others (includes corresponding Graph/Chart).......246
Development Pipeline.......246
1$350
   Hepatitis B Vaccine in India.......247
Panacea Biotec: A Leading Manufacturer of Hepatitis B Vaccine.......247
1$100
   Combination Vaccines.......248
Indian Vaccine Market - Combination Vaccines Available in the Country.......248
1$100
   Indian Vaccine Market: New Combination Vaccines under Development by Major Companies
  As of 2010.......249
International Players Entering the Arena.......249
Major Partnerships Between Indian and International Players: A Recent Past
  Data.......249
Heading Towards Greener Pastures.......249
1$100
   The Patent Act (Third Amendment), 2005.......250
Select Players.......250
GreenCross Vaccine Co., Ltd. (South Korea).......250
Human Biologicals Institute (India).......250
1$100
   Panacea Biotec Limited (India).......251
Serum Institute of India, Ltd. (India).......251
Wockhardt Limited (India).......251
1$100
   B. Market Analytics.......252
Table 108: Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......252
1$350
   Table 109: Asia-Pacific Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......253

Table 110: Asia-Pacific 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......253
1$350
  20. LATIN AMERICA.......2543 $950  
   A. Market Analysis.......254
Overview and Outlook.......254
Table 111: Leading Players in the Vaccines Market in Latin America (2008): Market Share Breakdown of Value Sales for Sanofi Pasteur, Wyeth, GlaxoSmithKline, Merck, Novartis, and Others (includes corresponding Graph/Chart).......254
Need for an effective TB Vaccine in Brazil.......254
1$350
   B. Market Analytics.......255
Table 112: Latin America Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......255
1$350
   Table 113: Latin America Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......256

Table 114: Latin America 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/ Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......256
1$350
  21. REST OF WORLD.......2572 $595  
   Market Analysis.......257
Table 115: Rest of World Recent Past, Current & Future Analysis for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).......257
1$350
   Table 116: Rest of World Historic Review for Human Vaccines (Prophylactic) by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).......258

Table 117: Rest of World 11-Year Perspective for Human Vaccines (Prophylactic) by Product Group/Segment – Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for 2005, 2010 & 2015.......258
1$350
COMPETITION 528$995
  
Total Companies Profiled: 162 (including Divisions/Subsidiaries - 194)

Region/Country                 Players


The United States                 84    
Canada                             5
Japan                              8
Europe                            53 
     France                        8
     Germany                       5
     The United Kingdom            9
     Italy                         3
     Spain                         2
     Rest of Europe               26 
Asia-Pacific (Excluding Japan)    41 
Latin America                      1
Africa                             1
Middle-East                        1
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign